Eli Lilly's Weight Loss Pill Clears Way During Latest Trial, Approval May Come Soon

Eli Lilly's obesity pill clears final trial, paving way for global approval

Eli Lilly's Orforglipron helped patients with obesity and Type 2 diabetes lose over 10% body weight in phase 3 trials, setting stage for global approval of the first no-restrictions oral pill.

Eli Lilly’s weight loss pill clears latest trial

US pharma giant Eli Lilly said its anti-obesity pill hit weight loss targets in a recent trial, boosting its efforts to compete in the expanding market. The findings help Lilly counter earlier trial results that underwhelmed investors, showing how closely the market is watching the development of anti-obesity pills, which would cost less than current injectable GLP-1 medications. Danish rival Novo Nordisk submitted its first weight loss pill for…

Eli Lilly's weight loss pill clears way during latest trial, approval may come soon

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and Type 2 diabetes.

Eli Lilly eyes orforglipron approval after Phase III diabetes trial success

A new release of Phase III data in diabetic patients related to Eli Lilly’s orforglipron signals a positive turnaround for the oral GLP-1RA.  The post Eli Lilly eyes orforglipron approval after Phase III diabetes trial success appeared first on Clinical Trials Arena.

Eli Lilly eyes orforglipron approval after Phase III diabetes trial success - Pharmaceutical Technology

A new release of Phase III data in diabetic patients related to Eli Lilly’s orforglipron signals a positive turnaround for the oral GLP-1RA.

Eli Lilly’s Oral GLP-1 Weight-Loss Pill Clears Third Phase 3 Trial, Bringing FDA Approval Within Reach

Lilly's oral GLP-1 orforglipron succeeds in third Phase 3 trial, prompting global obesity regulatory submissions this year.